Cargando…

A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model

We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-envelope and –liposome (HSP65 + IL-12/HVJ). This vaccine provided remarkable...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, M., Kita, Y., Nakajima, T., Kanamaru, N., Kaneda, Y., Saunderson, P., Tan, E.V., McMurray, DN.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129750/
https://www.ncbi.nlm.nih.gov/pubmed/32288912
http://dx.doi.org/10.1016/j.provac.2011.07.007
_version_ 1783516856096653312
author Okada, M.
Kita, Y.
Nakajima, T.
Kanamaru, N.
Kaneda, Y.
Saunderson, P.
Tan, E.V.
McMurray, DN.
author_facet Okada, M.
Kita, Y.
Nakajima, T.
Kanamaru, N.
Kaneda, Y.
Saunderson, P.
Tan, E.V.
McMurray, DN.
author_sort Okada, M.
collection PubMed
description We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-envelope and –liposome (HSP65 + IL-12/HVJ). This vaccine provided remarkable protective efficacy in mouse model compared to the BCG. This vaccine also provided therapeutic efficacy against multi-drug resistant TB (MDR-TB) and extremely drug resistant TB (XDR-TB) in murine models. Furthermore, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis. This novel vaccine provided a higher level of the protective efficacy than BCG based upon the assessment of mortality. The BCG prime and HSP65 + IL-12/HVJ vaccine (boost) by the prime-boost method showed a synergistic prophylactic effect in the monkey. Furthermore, this vaccine exerted therapeutic efficacy (100% survival) and augmentation of immune responses in the TB-infected monkeys.HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine increased the body weight of TB-infected monkeys, improved the ESR, and augmented the immuneresponses (proliferation of PBL and IL-2 production). The enhancement of IL-2 production from monkeys treated with this vaccine was correlated with the therapeutic efficacy of the vaccine. These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials.
format Online
Article
Text
id pubmed-7129750
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71297502020-04-08 A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model Okada, M. Kita, Y. Nakajima, T. Kanamaru, N. Kaneda, Y. Saunderson, P. Tan, E.V. McMurray, DN. Procedia Vaccinol Article We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-envelope and –liposome (HSP65 + IL-12/HVJ). This vaccine provided remarkable protective efficacy in mouse model compared to the BCG. This vaccine also provided therapeutic efficacy against multi-drug resistant TB (MDR-TB) and extremely drug resistant TB (XDR-TB) in murine models. Furthermore, we extended our studies to a cynomolgus monkey model, which is currently the best animal model of human tuberculosis. This novel vaccine provided a higher level of the protective efficacy than BCG based upon the assessment of mortality. The BCG prime and HSP65 + IL-12/HVJ vaccine (boost) by the prime-boost method showed a synergistic prophylactic effect in the monkey. Furthermore, this vaccine exerted therapeutic efficacy (100% survival) and augmentation of immune responses in the TB-infected monkeys.HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine increased the body weight of TB-infected monkeys, improved the ESR, and augmented the immuneresponses (proliferation of PBL and IL-2 production). The enhancement of IL-2 production from monkeys treated with this vaccine was correlated with the therapeutic efficacy of the vaccine. These data indicate that our novel DNA vaccine might be useful against Mycobacterium tuberculosis including XDR-TB and MDR-TB for human therapeutic clinical trials. Published by Elsevier B.V. 2011 2011-09-29 /pmc/articles/PMC7129750/ /pubmed/32288912 http://dx.doi.org/10.1016/j.provac.2011.07.007 Text en Copyright © 2011 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Okada, M.
Kita, Y.
Nakajima, T.
Kanamaru, N.
Kaneda, Y.
Saunderson, P.
Tan, E.V.
McMurray, DN.
A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model
title A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model
title_full A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model
title_fullStr A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model
title_full_unstemmed A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model
title_short A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model
title_sort novel therapeutic and prophylactic vaccine against tuberculosis using the cynomolgus monkey model and mouse model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129750/
https://www.ncbi.nlm.nih.gov/pubmed/32288912
http://dx.doi.org/10.1016/j.provac.2011.07.007
work_keys_str_mv AT okadam anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT kitay anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT nakajimat anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT kanamarun anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT kaneday anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT saundersonp anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT tanev anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT mcmurraydn anoveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT okadam noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT kitay noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT nakajimat noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT kanamarun noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT kaneday noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT saundersonp noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT tanev noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel
AT mcmurraydn noveltherapeuticandprophylacticvaccineagainsttuberculosisusingthecynomolgusmonkeymodelandmousemodel